Albert Bourla, Pfizer CEO (John Thys, Pool/AFP via Getty Images)

Break­ing: Pfiz­er's Covid-19 an­tivi­ral re­duces hos­pi­tal­iza­tions by 89%, could prove a for­mi­da­ble foe for Mer­ck­'s pill

Pfiz­er on Fri­day un­veiled sta­tis­ti­cal­ly sig­nif­i­cant ef­fi­ca­cy da­ta for its po­ten­tial Covid-19 pill among peo­ple who haven’t been hos­pi­tal­ized with the virus. The da­ta will like­ly lead to a quick EUA from the FDA and add to a grow­ing field of ef­fec­tive, easy-to-use treat­ments.

Da­ta from a sched­uled in­ter­im analy­sis showed an 89% re­duc­tion in risk of Covid-re­lat­ed hos­pi­tal­iza­tion or death from any cause com­pared to place­bo in pa­tients treat­ed with­in three days of symp­tom on­set. Pfiz­er said it halt­ed en­roll­ment in the tri­al be­cause of the pos­i­tive re­sults, and in con­sul­ta­tion with the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.